Researchers find ways to improve Kalydeco CF treatment; IntelGenx, RedHill introduce oral 'film' for migraines;

> Vertex's ($VRTX) Kalydeco, the first drug to treat the genetic causes of cystic fibrosis, may be more effective and targeted, researchers at the University of Missouri said. Article

> IntelGenx, along with RedHill Biopharma, submitted an NDA for a migraine treatment to be delivered orally as a thin, dissolving film, releasing the drug Rizatriptan. Release

> The FDA approved Becton, Dickinson and Company's line of prefilled generic injectables, which are designed to cut down on medication error and preparation time during injections. Release

> Zimmer Holdings launched an injectable pain relief gel to treat knee arthritis for patients who didn't respond to other steroids and pain relievers. Gel-One Hyaluronate benefits from the texture of its material, which is created via a cross-linking process. Story

> Researchers at the University of California have developed a leukemia treatment using a human antibody that targets and destroys the cells. More